News
PSTV
1.300
-0.76%
-0.010
Here are the major earnings after the close today
Seeking Alpha · 13h ago
Earnings Scheduled For November 14, 2024
Benzinga · 19h ago
A Peek at Plus Therapeutics's Future Earnings
Benzinga · 1d ago
ProPhase Labs, Inc. (PRPH) Reports Q3 Loss, Tops Revenue Estimates
NASDAQ · 1d ago
Plus Therapeutics Inc <PSTV.OQ> expected to post a loss of 56 cents a share - Earnings Preview
Reuters · 2d ago
Organogenesis (ORGO) Tops Q3 Earnings and Revenue Estimates
NASDAQ · 2d ago
Weekly Report: what happened at PSTV last week (1104-1108)?
Weekly Report · 3d ago
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 11/07 12:05
Plus Therapeutics and Spectronrx partner for radiotherapeutic manufacturing
Seeking Alpha · 11/06 13:40
PLUS THERAPEUTICS AND SPECTRONRX ANNOUNCE RADIOTHERAPEUTIC MANUFACTURING PARTNERSHIP
Reuters · 11/06 12:30
Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024
Barchart · 11/05 06:30
Zoetis (ZTS) Q3 Earnings and Revenues Beat Estimates
NASDAQ · 11/04 13:10
Weekly Report: what happened at PSTV last week (1028-1101)?
Weekly Report · 11/04 09:54
Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, Texas
Barchart · 10/29 06:30
Weekly Report: what happened at PSTV last week (1021-1025)?
Weekly Report · 10/28 09:50
Weekly Report: what happened at PSTV last week (1014-1018)?
Weekly Report · 10/21 09:49
Weekly Report: what happened at PSTV last week (1007-1011)?
Weekly Report · 10/14 09:59
Weekly Report: what happened at PSTV last week (0930-1004)?
Weekly Report · 10/07 09:55
Plus Therapeutics files $100M mixed securities shelf
TipRanks · 10/05 08:22
Biotech Alert: Searches spiking for these stocks today
TipRanks · 10/05 07:18
More
Webull provides a variety of real-time PSTV stock news. You can receive the latest news about Plus Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About PSTV
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Its radiotherapeutic candidate, rhenium (186Re) obisbemeda, is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC). The Company’s Rhenium (186Re) obisbemeda, a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers.